ArticleIranian journal of microbiology2019
Prevalence of hepatitis E virus in thalassemia patients with hepatitis C in Tehran, Iran.
Article in Iranian journal of microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
- Seroprevalence of Hepatitis E Virus Infection in Middle Eastern Countries: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2022Pooled it
- HEV Infection in Beta-Thalassemia Patients.Pathogens (Basel, Switzerland) · 2024Review
- Article
- Higher Risk of Chronic Hepatitis E Virus Infection in Patients with Human Immunodeficiency Virus-1: An Iranian Cross-sectional Study.Iranian journal of pathology · 2023Article
- Transfusion-transmitted hepatitis E: What we know so far?World journal of gastroenterology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesHEV infection is predominantly spread via the fecal-oral route; however, due to the presence of HEV RNA in the serum of healthy blood donors, there is a possibility of the transmissibility of HEV infection through blood. Multi-transfused thalassemia patients are one of the high risk groups for blood borne viruses. In this study, we evaluated the prevalence of HEV antibodies and HEV-RNA in thalassemia patients with HCV infection. MATERIALS AND
methods120 anti-HCV positive thalassemia patient serum samples from Tehran province during April-June 2019 were assessed for the presence of total anti-HEV antibodies using of HEV Ab ELISA kit. All serum samples were assayed by Nested RT-PCR to detect HEV-RNA.
resultsThe results of ELISA test showed that 2 out of 120 (1.67%) samples were positive for anti-HEV Ab. There was no statistically significant difference between anti-HEV antibody prevalence rate and sex, age and other risk factors. None of 120 (0.00%) samples were positive for HEV-RNA by Nested RT-PCR.
conclusionSeroprevalence of HEV in our study group was 1.67% which is less than HEV seroprevalence rate in Iranian general population. Therefore, it can be conclude that transmission of HEV infection via blood transfusion seems to be uncommon in Iran and the fecal-oral route can be the predominant mode of transmission in Iran; however, more studies are required to confirm this issue.
Indexed as
Identifiers
32148686PMC7048959W3000277272What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.